RIPK1 is SUMOylated at K550, and the SUMOylation of RIPK1 promotes its activation, which is reversed by SUMO-specific protease 1 (SENP1), inhibiting cell death and the development of non-alcoholic steatohepatitis [138] (Figure 1A and Figure 2A,B and Table 1). This evidence concerns the gene RIPK1 and metabolic dysfunction-associated steatohepatitis.